BIOMAT Database Logo BIOMAT Database Logo

Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. 2002

Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. micaela.hernberg@hus.fi

OBJECTIVE Pulmonary toxicity was prospectively evaluated within a randomized trial for breast cancer patients at high risk for relapse, who postoperatively received as adjuvant therapy either 9 cycles of tailored chemotherapy (20 patients) (cyclophosphamide, epirubicin, 5-fluorouracil [FEC]) or standard FEC x 3 followed by high-dose chemotherapy (cyclophosphamide, thiotepa, carboplatin [CTCb]) supported by peripheral blood stem cell transplantation (14 patients). After high-dose chemotherapy or tailored FEC, all patients received locoregional radiotherapy (50 Gy/5 weeks), plus tamoxifen for 5 years. METHODS Lung function tests (FVC, FEV1, and DL(CO)) were performed before chemotherapy and 9 months after radiotherapy. Computed tomography of the lungs was performed before radiotherapy and 6 weeks, 3 months, and 9 months after radiotherapy. RESULTS Clinical signs of suspected pneumonitis were noted in 29% of patients, but only 1 patient needed symptomatic therapy. Radiologic changes were detected in 68% of patients, and they were most frequent at 3 months after radiotherapy. FVC decreased in both groups (tailored FEC: mean difference, -6.5%, p = 0.0005; CTCb: -2.0%, p = 0.21; tailored FEC vs. CTCb: -4.5%, p = 0.05). DL(CO) decreased significantly in both groups (tailored FEC: mean difference, -11.2%, p < 0.0001; CTCb: -5.6%, p = 0.02; tailored FEC vs. CTCb: -5.6%, p = 0.07). FEV1 decreased by 7.3% in patients treated with tailored FEC (p < 0.0001) and by 2.5% in patients treated with CTCb (p = 0.03) (tailored FEC vs. CTCb: 3.7%, p = 0.08). CONCLUSIONS Changes in pulmonary function were thus detected in both groups, although to a greater extent in the tailored FEC group. The clinical significance of these findings should be balanced carefully against the improved, statistically significant relapse-free survival achieved with the tailored FEC regimen compared to high-dose CTCb + peripheral blood stem cell transplantation (PSCT).

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.
August 2019, Annals of surgical oncology,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Customising radiotherapy in stage II breast cancer after primary chemotherapy.
September 2022, The Lancet. Oncology,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Late radiation toxicity after intraoperative radiotherapy (IORT) for breast cancer: results from the randomized phase III trial TARGIT A.
August 2012, Breast cancer research and treatment,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
December 2005, Journal of the National Cancer Institute,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
November 2011, International journal of radiation oncology, biology, physics,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Understanding changes in pulmonary function and functional status in breast cancer patients after systemic chemotherapy and radiotherapy: a prospective study.
February 2024, BMC pulmonary medicine,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy.
January 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
[Second primary cancers after radiotherapy in breast cancer patients].
October 2013, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Post-mastectomy radiotherapy after neodjuvant chemotherapy in breast cancer patients: A review.
March 2015, Critical reviews in oncology/hematology,
Micaela Hernberg, and Pekka Virkkunen, and Paula Maasilta, and Jani Keyriläinen, and Carl Blomqvist, and Jonas Bergh, and Tom Wiklund
Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
December 2012, Current medical research and opinion,
Copied contents to your clipboard!